fungemia

(redirected from Invasive candidiasis)
Also found in: Dictionary.

fungemia

 [fun-je´me-ah]
the presence of fungi in the blood stream.

fun·ge·mi·a

(fŭn-jē'mē-ă),
Fungal infection disseminated by way of the bloodstream.

fungemia

[funjē′mē·ə]
Etymology: L, fungus + Gk, haima, blood
the presence of fungi in the blood, mostly seen in immunocompromised patients. Diagnosis is difficult because routine blood cultures have poor sensitivity. Compare bacteremia, parasitemia, viremia.

fun·ge·mi·a

(fŭn-jē'mē-ă)
Fungal infection disseminated by way of the bloodstream.
Synonym(s): fungaemia.

fungemia

the presence of fungi in the bloodstream.
References in periodicals archive ?
Mucocutaneous and invasive candidiasis among very low birth weight (less than 1,500 grams) infants in intensive care nurseries: a prospective study.
Breakthrough invasive candidiasis in patients on micafungin.
This was decided based on the fact that invasive candidiasis is difficult to diagnose [5,18,19] and that candida colonization of non-sterile sites, although non-specific, can be a marker of systemic disease [18,19].
Nine infants developed invasive candidiasis and six of them died during the 2 years prior to introduction of the prophylaxis.
He and his colleagues examined caspofungin efficacy for 109 episodes of invasive candidiasis at Duke University Medical Center.
The failure rate for invasive candidiasis at Duke decreased from 26% in 2001 to 11% in 2003.
Newer approaches for the diagnosis of invasive candidiasis have included the detection of various Candida cell wall and cytoplasmic antigens in blood and other sterile body fluids.
14 One-tenth of our patients were receiving total parenteral nutrition (TPN), identified in many multivariate studies to be an independent risk factor for invasive candidiasis and candidemia.
We were seeing a lot of cases of invasive candidiasis in newborns," Jaime G.
Patients in an open-label, randomized phase II study received 50-mg, 75-mg, or 100-mg doses of anidulafungin to treat invasive candidiasis.
Drug company SCYNEXIS (NasdaqGM:SCYX) disclosed on Friday the receipt of US Food & Drug Administration's (FDA) Fast Track designation for the oral formulation of SCY-078 for the treatment of invasive Candidiasis, including Candidemia and invasive Aspergillosis.

Full browser ?